MX2020003786A - Composiciones orales para el tratamiento de reflujo gastroesofagico. - Google Patents

Composiciones orales para el tratamiento de reflujo gastroesofagico.

Info

Publication number
MX2020003786A
MX2020003786A MX2020003786A MX2020003786A MX2020003786A MX 2020003786 A MX2020003786 A MX 2020003786A MX 2020003786 A MX2020003786 A MX 2020003786A MX 2020003786 A MX2020003786 A MX 2020003786A MX 2020003786 A MX2020003786 A MX 2020003786A
Authority
MX
Mexico
Prior art keywords
treatment
oral compositions
gastroesophageal reflux
composition
gastroesophageal
Prior art date
Application number
MX2020003786A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Paola Maffei
Marco Mascagni
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of MX2020003786A publication Critical patent/MX2020003786A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe una composición mucoadhesiva que comprende sulfato de condroitina, xiloglucano y glicerol para uso en el tratamiento y prevención de flujo gastroesofagico; también se describe un procedimiento para la preparación de tal composición, una forma de dosificación para su administración y un kit que comprende la misma.
MX2020003786A 2017-09-28 2018-09-18 Composiciones orales para el tratamiento de reflujo gastroesofagico. MX2020003786A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000108526A IT201700108526A1 (it) 2017-09-28 2017-09-28 Composizioni orali per il trattamento del refluso gastroesofageo.
PCT/EP2018/075200 WO2019063363A1 (en) 2017-09-28 2018-09-18 ORAL COMPOSITIONS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL REFLUX

Publications (1)

Publication Number Publication Date
MX2020003786A true MX2020003786A (es) 2020-08-03

Family

ID=61024911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003786A MX2020003786A (es) 2017-09-28 2018-09-18 Composiciones orales para el tratamiento de reflujo gastroesofagico.

Country Status (7)

Country Link
US (1) US11241452B2 (es)
EP (1) EP3687494A1 (es)
CN (2) CN111093628B (es)
EA (1) EA202090827A1 (es)
IT (1) IT201700108526A1 (es)
MX (1) MX2020003786A (es)
WO (1) WO2019063363A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000022471A1 (it) * 2020-09-23 2022-03-23 Sofar Swiss Sa Composizioni comprendenti una condroitina vegetale o un suo analogo e loro uso nel trattamento disturbi della mucosa del tratto orale, faringo-laringeo e/o gastro-esofageo
TWI777673B (zh) * 2021-07-16 2022-09-11 陳昭誠 由β-1-4-葡聚醣形成之纖維於製備用於治療或預防胃食道逆流之組成物之用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7201998A (en) * 1997-05-06 1998-11-27 Zhi Liu Drug delivery system
GB9910212D0 (en) 1999-05-05 1999-06-30 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US7504387B2 (en) 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
GB2398496A (en) * 2003-02-20 2004-08-25 Reckitt Benckiser Healthcare Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
DE202008017456U1 (de) * 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
US9241953B2 (en) * 2008-05-13 2016-01-26 Apharm S.R.L. Glycosaminoglycan oral use and compositions
PT2296670E (pt) 2008-05-13 2013-03-25 Apharm Srl Utilização oral de glicosaminoglicana e composições
EP2208500A1 (en) * 2009-01-16 2010-07-21 Bionap S.r.L. Compositions for the treatment of gerd (gastroesophageal reflux disease)
PT2435021E (pt) 2009-05-25 2013-09-30 Sofar Swiss Sa Utilização de uma combinação fixa de glicosaminoglicano e composição mastigável compreendendo a referida combinação fixa
IT1397132B1 (it) * 2009-12-01 2013-01-04 Alfa Wassermann Spa Composizioni comprendenti antiinfiammatori non steroidei.
JP2014501258A (ja) * 2010-12-23 2014-01-20 コルゲート・パーモリブ・カンパニー 構造化剤を含む流体組成物

Also Published As

Publication number Publication date
WO2019063363A1 (en) 2019-04-04
IT201700108526A1 (it) 2019-03-28
CN111093628B (zh) 2023-11-17
CN117503794A (zh) 2024-02-06
EP3687494A1 (en) 2020-08-05
US11241452B2 (en) 2022-02-08
EA202090827A1 (ru) 2020-06-24
CN111093628A (zh) 2020-05-01
US20190314402A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
SV2018005778A (es) Derivados aromaticos de sulfonamida
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
HN2012001162A (es) Triazolopiridinas
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CR10347A (es) Anticuerpos contra el peptidob-amiloide
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
IL273300A (en) High dose valbenazine formulation and related preparations, methods and kits
GT201300254A (es) Triazolopiridinas
CU20200042A7 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
MX2016011897A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112022002653A2 (pt) Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit de partes
MX2020004810A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
BR112016022722B8 (pt) Composto, composição farmacêutica que o comprende e uso do mesmo
MX2020003786A (es) Composiciones orales para el tratamiento de reflujo gastroesofagico.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
JP2020506196A5 (ja) テビペネムピボキシル結晶形、それを含む組成物、製造方法、および使用方法
BR112015030343A8 (pt) uso de um adjuvante de lipídeo de glicopiranosila (gla) e composição farmacêutica compreendendo o referido adjuvante
IT201700085412A1 (it) Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare